Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters
Open Access
- 1 March 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (13) , e6469
Abstract
The objective of the present study was to assess the effect of cyclosporine (CsA) on the pharmacokinetic parameters of mycophenolic acid (MPA), an active mycophenolate mofetil (MMF) metabolite, and to compare with the effect of everolimus (EVR). Anonymized medical records of 404 kidney recipients were reviewed. The main MPA pharmacokinetic parameters (AUC(0–12) and Cmax) were evaluated. The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0–12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05). A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01). The comparative analysis between 2 treatment arms (MMF + CsA and MMF + EVR) showed that MPA AUC(0–12) exposure was by 43% higher in the patients treated with a medium dose of MMF and EVR than in the patients treated with a medium dose of MMF and CsA. The data of the present study suggest a possible CsA versus EVR influence on MMF pharmacokinetics. Study results show that CsA has an impact on the main MPA pharmacokinetic parameters (AUC(0–12) and Cmax) in a CsA dose-related manner, while EVR mildly influence or does not affect MPA pharmacokinetic parameters. Low-dose CsA (lower than 180 mg/day) reduces MPA AUC(0–12) exposure under the therapeutic window and may lead to ineffective therapy, while a high-dose CsA (>240 mg/day) is related to greater than 10 mg/L MPA Cmax and increases the likelihood of adverse events.Keywords
This publication has 51 references indexed in Scilit:
- Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipientsJournal of Pharmacokinetics and Pharmacodynamics, 2009
- Immunotherapy in Elderly Transplant RecipientsDrugs & Aging, 2009
- Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approachThe European Journal of Health Economics, 2009
- A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patientsBritish Journal of Clinical Pharmacology, 2006
- Influence of Co‐Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney TransplantationAmerican Journal of Transplantation, 2005
- Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modellingBritish Journal of Clinical Pharmacology, 2005
- Cyclosporin A, but Not Tacrolimus, Inhibits the Biliary Excretion of Mycophenolic Acid Glucuronide Possibly Mediated by Multidrug Resistance-Associated Protein 2 in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Concentrations in Stable Renal Transplant PatientsClinical Pharmacokinetics, 2004
- Maximum A Posteriori Bayesian Estimation of Oral Cyclosporin Pharmacokinetics in Patients with Stable Renal TransplantsClinical Pharmacokinetics, 2002
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999